New rehab model aims to boost recovery for stomach and esophageal cancer patients
NCT ID NCT05698992
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized rehabilitation program for people recovering from surgery for esophageal or gastric cancer. Participants will receive a structured assessment of their physical, psychological, and social needs, followed by evidence-based support. The goal is to improve quality of life and reduce cancer-related symptoms. The trial involves 100 adults in southern Sweden who are scheduled for curative surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- structured individualized rehabilitation program
- What this could lead to
- If it works, this could provide a proven model to help people with esophageal or gastric cancer recover better and have a higher quality of life after surgery.
- What could go wrong
- This is a small, early-stage trial (100 participants) testing a care model, not a drug. Results may not apply to all patients or regions, and the intervention may not show significant benefit over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
\*patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden (Skåne), and are planned to undergo or has undergone curative surgerytreatment at Skåne University Hospital.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * over 18 years of age * esophageal or gastric cancer * living in Southern Sweden (Skåne) * are planned to undergo curative surgerytreatment at Skåne University Hospital. Exclusion Criteria: * unable to communicate in the Swedish language * suffering from a cognitive impairment that poses a barrier for participating in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Skåne University Hospital
RECRUITINGLund, Lund, 222 42, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One small incision vs several: robotic stomach cancer surgery put to the test
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?